



Analysis of Drug Use in Non-Ventilator Covid-19 Patients at Bangil Hospital

Vincentina Yenny Triamyanti¹, Fauna Herawati², Rika Yulia^{2*}, Abdul Kadir Jaelani³

¹Master of Pharmacy Study Program, Faculty of Pharmacy, University of Surabaya, Surabaya, Indonesia

²Department of Clinical and Community Pharmacy, Faculty of Pharmacy, University of Surabaya, Surabaya, Indonesia

³Pharmacy Installation Training Unit, Bangil Regional General Hospital, Pasuruan, Indonesia

*Corresponding author: rika_y@staff.ubaya.ac.id

Submitted: 19 April 2022

Accepted: 14 July 2022

Published: 31 August 2022

Abstract

Background: *Coronavirus Disease 2019 (Covid-19) is an infectious disease. Common signs and symptoms of Covid-19 infection include acute respiratory distress such as fever, cough and shortness of breath. Analysis of drug use in Non-Ventilator Covid-19 patients needs to be carried out to provide an overview of drug therapy currently being used based on the Covid-19 Management Guidelines Edition 3rd because so far, there has not been a single type of drug that has received marketing authorization for Covid-19 therapy. Objectives: This study aims to determine patient profiles, therapeutic outcomes, suitability of drug use with Covid-19 Management Guidelines 3rd edition, the quantity of antibiotic use using the DDD/100 patient-days method and antivirals. Methods: The method used in this study is an observational design study which was analyzed descriptively with retrospective data collection. Result: Based on the profile of drug use in COVID-19 patients, there are 31 types of drug classes. The most consumed drugs were antibacterial (91%) and analgesics (91%), followed by vitamins (89%) and supplements (85%). Based on the DDD/100 patient-days value, the most widely used antibiotics were Azithromycin. Conclusion: The patient's profile at the time of admission to the hospital was 44% moderate and 56% severe. The condition of patients at the time of discharge from the hospital with a moderate degree using antivirals and antibiotics were more recovered and returned home with improvements with percentages of 84.1% and 88.64%, respectively.*

Keywords: *covid-19, non-ventilator patients, antibiotic, antiviral*

How to cite this article:

Triamyanti, V.Y., Herawati, F., Yulia, R. & Jaelani, A.K. (2022). Analysis of Drug Use in Non-Ventilator Covid-19 Patients at Bangil Hospital. *Jurnal Farmasi Dan Ilmu Kefarmasian Indonesia*, 9(2), 168-176. <http://doi.org/10.20473/jfiki.v9i22022.168-176>

INTRODUCTION

Infectious disease is a disease that often occurs throughout the world. The cause of this infection is a new type of virus called Severe Acute Respiratory Syndrome Coronavirus-2 or SARS-CoV-2. WHO named the disease Coronavirus Disease 2019 or Covid-19 through consultation and collaboration with the World Organization for Animals (OIE) and the Food and Agriculture Organization of the United Nations (FAO). Common signs and symptoms of Covid-19 infection include acute respiratory distress such as fever, cough, and shortness of breath. The average incubation period is 5-6 days, with the most prolonged incubation period being 14 days. Severe cases of Covid-19 can lead to pneumonia, acute respiratory syndrome, kidney failure, and even death.

Transmission of the Covid-19 virus can occur through respiratory droplets (aerosol), direct contact with contaminated objects and surfaces from sufferers, and both asymptomatic and symptomatic (WHO, 2021). On January 30th, 2020, this virus spread rapidly and caused an exponential increase in the number of patients until July 9th, 2020. WHO reported 11,840,226 confirmed cases with 545,481 deaths worldwide (Case Fatality Rate/CFR 4.6%) (WHO, 2021). Based on the condition and severity of Covid-19 cases, they are divided into several categories: asymptomatic, mild, moderate, severe, and critical. Based on an earlier study, from the profile of Covid-19 patients for the period January to April 2021 at RSU Haji Surabaya from 100 patients, the results showed that 61% were Covid-19 patients in the moderate category and 39% were in a severe category. Among patients in moderate category, 90.16% recovered while 9.84% died. From the profile of drug use in COVID-19 patients for the period January to April 2021 at RSU Haji from 100 patients, the results showed 99% of patients used mucolytic drugs by 99%, and the second most used was vitamin class drugs, which was 98%, then followed by the use of antibiotics class of drugs by 97%, and the fourth is antiviral drugs by 96% (Isna, 2021).

Following the Covid-19 therapy guidelines from WHO, Indonesia has recommended supportive therapy for handling Covid-19, such as symptom therapy, supplemental oxygen, antibiotics, fluid therapy, vasopressors, and medical measures (including installing a ventilator) to save the patient's life (Setiadi et al., 2020). Repurposing drugs is the use of drugs that already exist and are not officially indicated for Covid-19 but are used as therapy through an efficient approach.

(Singh et al., 2020). According to the guidelines for managing Covid-19 therapy in Indonesia, which refers to the WHO, empirical antibiotics are given as therapy for Covid-19 patients to overcome secondary bacterial infections (Burhan et al., 2020). Data on the use of antibiotics in Covid-19 patients shows that antibiotics rank first in the treatment of Covid-19 with a percentage of 90.83% (Gutiérrez et al., 2020). The most widely used antibiotics are ceftriaxone 69.28%, azithromycin 67.93%, and levofloxacin 15.2%. Other therapies used for Covid-19, among others, are antimalarials by 44.37%, with the use of hydroxychloroquine ten times greater than chloroquine (64.95%: 6.13%), the use of steroids by 44.37%, and the use of the antiviral lopinavir-ritonavir by 42.63% and tocilizumab by 9.37% (Gutierrez et al., 2020). Analysis of drug use in Non-Ventilator Covid-19 patients needs to be carried out to provide an overview of drug therapy currently being used based on the Covid-19 Management Guidelines 3rd Edition because so far, there has not been a single type of drug that has received marketing authorization for Covid-19 therapy. Reminding the high cases of Covid-19 and the efforts of all parties to obtain the best therapeutic data in perfecting the management of Covid-19 therapy, this study aims to determine patient profiles, therapeutic outcomes, suitability of drug use with Covid-19 Management Guidelines 3rd edition, the quantity of antibiotic use using the DDD/100 patient-days method, and the use of antivirals at Bangil Hospital.

METHOD

This research was an observational research design which used a retrospective descriptive design. The data sources were medical records and records of drug use from the Department of Hospital Pharmacy. The population in this research were Covid-19 patients with moderate or severe categories of hospitalization who received treatment at Bangil Hospital. The sample size was taken using the purposive sampling method, namely 100 COVID-19 patients who met the inclusion and exclusion criteria from all confirmed COVID-19 patients in the isolation room without a ventilator (moderate or severe).

Assessment and evaluation of the quantity of antibiotic use is carried out using the Defined Daily Dose. The calculation of the Defined Daily Dose was as follows:

$$\frac{DDD}{100} \text{ Patient - Days} = \frac{\text{Medicine in grams used by all patient} \times 100}{DDD \text{ WHO standard in grams LOS}}$$

The reliability and accuracy of drug use in percentage units compared with the Covid-19 Management Manual 3rd Edition 2020. This research used ICD-10 and ATC codes to shorten the presentation table by grouping. This research also received an Ethics Certificate from the Bangil Hospital Ethics Number 445.1/026/424.072.01/2021.

RESULTS AND DISCUSSION

Coronavirus disease has been identified since 2019 (Covid-19) and is associated with the cause of many deaths. It has been reported that the most susceptible to Covid-19 are elderly patients with a 6-fold higher risk. Based on the severity of cases, Covid-19 is divided into 5 levels: asymptomatic, mild, moderate, severe and critical. This shows that the treatment or therapy given must be different for each so as not to worsen the patient's condition (PDPI et al., 2020). In this situation, it is necessary to conduct a drug analysis for non-ventilator Covid-19 patients.

Samples were classified by their severity. Each level of severity was further classified based on age, sex, and length of hospitalization. The sample data showed that most of the moderate Covid-19 patients were 36-45 years old (late adulthood) and 46-55 years old (early elderly), with a percentage of 22%. Moreover, most patients with the severe category were 56-65 years old (elderly), with 17%. Based on the length of hospitalization, the severe category takes longer than moderate severity.

Based on the demographic data, the sample was divided according to age and gender. The result shows that the highest percentage is at 36-45 years (late adulthood). This age group is the most affected by Covid-19 because of the frequent contact with patients. Meanwhile, based on gender, the most affected by Covid-19 are males. This is due to hormonal and immune conditions, and viral receptor enzymes are more commonly found in the male. The enzyme in question is Angiotensin-Converting Enzyme 2 (ACE 2) (Esmail et al., 2022).

Based on the demographic data, there were 100 samples. 44 samples (44%) were in the moderate category, and 56 samples (56%) were in a severe category. Moderate Covid-19 patients required hospitalization for 456 days, while patients with severe category of Covid-19 need 797 days for hospitalization. Factors that can affect the length of hospitalization are complications experienced by the patient. Patients with

comorbidities may experience complications that prolong hospitalization (Hiroyuki et al., 2021).

The results of the research samples in the moderate patient category indicated that there were 24 samples (24%) of male infected with Covid-19 and this number was more than female who only had 20 samples (20%). The results of the research sample for severe patient category based on gender showed that there were 32 samples of male patients (32%) infected with Covid-19, and this number was more than female patients who only had 24 samples (24%). This is in line with a study entitled Pandemic Covid-19 in a Demographic Perspective which stated that there were 51.5% male Covid-19 patients and only 48.5% female (Laura et al., 2021). Other studies have also found different behavior between males and females in maintaining their health. Females tend to care more about their health than males. In general, this behavior shows that females comply more with health protocols such as wearing masks, washing hands and keeping a distance (Goncalves et al., 2020).

Table 1. Severity Profile

Variable of Covid-19 Patients			
		Moderate	Severe
Age	17 – 25	7%	3%
	26 – 35	7%	5%
	36 – 45	12%	14%
	46 – 55	10%	13%
	56 – 65	7%	17%
	65 – over	1%	4%
Gender	Male	24%	32%
	Female	20%	24%
Length of stay		456 days	797 days
Mean		10	14

The sample data of severity affects the condition of patients out of the hospital. The exposure data can be seen in Table 2. The data showed that patients with moderate severity had no death cases, while 19 (33.93%) patients died in severe severity. The profile of the study sample based on the condition of discharge from the hospital was influenced by the severity. Patients with symptoms who were discharged from the hospital in a recovered state were more than those who were discharged in an improved state. None of the Covid-19 patients with moderate symptoms died. More patients with severe symptoms of Covid-19 returned home in a recovered state than in an improvement state. An improvement state means that the patients are still given drugs to support their recovery. Meanwhile,

patients with severe symptoms died. Thus, it can be concluded that the number of patients with recovered outcomes is greater than the number of deaths (Kim et al., 2020).

This study is in accordance with a study in Korea which stated that the study's total sample was 5621 patients, with a total of 5387 patients recovered and 234 patients died. The study also explained that most Covid-19 patients who died were due to worsening conditions and respiratory failure in the ICU (Luis et al., 2022). The criteria for recovered patients are asymptomatic, mild symptoms, moderate symptoms, or severe/critical symptoms, provided that the patients have met the criteria for the issuance of a warning letter based on the assessment of the doctor at the health facility where it is carried out or by the DPJP. The criteria consist of a thorough clinical study that includes improved radiological and blood examination carried out by the DPJP, stating that the patient is allowed to go home.

There is no action/treatment required by the patient, either related to COVID-19 or other health problems experienced by the patient (PDPI et al., 2020).

Complication regarding Covid-19 is mainly associated with pneumonia (Table 3). This can occur because Covid-19 attacks the respiratory tract, where there are many ACE2 receptors, causing the respiratory tract to weaken as Covid-19 takes host (Naoyuki et al., 2022). Inflammation of the lungs can trigger infection and worsen the inflammatory condition (Tsamrotul et al., 2020). Inflammatory conditions of the lungs due to infection can be categorized as pneumonia. Inflammation of the airways can lead to respiratory failure in patients. Respiratory failure can cause the patient's condition to worsen and even cause death. This condition needs to be considered so that Covid-19 patients do not experience a much worse condition (Somers et al., 2020).

Table 2. Profile of Research Samples Based on Severity and Outcome Patient

Severity	Outcome Patient			Total
	Healed	Repatriation	Died	
<u>Moderate Category Covid-19 Patients (44%)</u>	56.82%	43.18%	0%	100%
With antibiotics	50.00%	38.64%	0%	
Without antibiotics	6.81%	4.55%	0%	100%
Appropriate antibiotics	38.47%	25.64%	0%	
No appropriate antibiotics	20.51%	15.38%	0%	100%
With antivirals	54.55%	29.55%	0%	
Without antivirals	2.26%	13.64%	0%	100%
Appropriate antivirals	43.24%	32.44%	0%	
No appropriate antivirals	21.62%	2.70%	0%	100%
<u>Severe Category Covid-19 Patients (56%)</u>	53.57%	12.5%	33.93%	100%
With antibiotics	48.21%	10.71%	33.93%	
Without antibiotics	5.36%	1.79%	0%	100%
Appropriate antibiotics	38.46%	7.69%	29.92%	
No appropriate antibiotics	11.54%	5.77%	9.62%	100%
With antivirals	46.43%	12.50%	30.36%	
Without antivirals	7.14%	0%	3.57%	100%
Appropriate antivirals	44.00%	14.00%	32.00%	
No appropriate antivirals	8.00%	0%	2.00%	100%

Table 3. Profile of Research Samples Based on Diagnosis of Comorbidities

ICD-10 Code Grouping	Code	Percentage of Patients (%)	Diagnosis	ICD-10 Code	Percentage (%)		
A00-B99	A	47	Gastroenteritis	A08.4	12		
			Tuberculosis	A15	3		
			Sepsis	A41.9	34		
D50-D89	B	2	Hepatitis C	B17.9	2		
			D	14	Anemia	D64.9	2
					Hypercoagulation	D68.69	11
E00-E90	E	22	Thrombocytopenia	D69.6	1		
			Diabetes mellitus	E10	19		
			Hypoglycemia	E16	1		
			Dyslipidemia	E78.5	3		
			Hyponatremia	E87.1	1		
			Hyperkalemia	E87.5	1		
			Hypoalbumin	E88.9	2		
H60-H95	H	2	Vertigo	H81.399	2		
			Hypertension	I10	2		
I00-I99	I	11	Acute Coronary Syndrome/ACS	I24.9	3		
			Heart Failure / HF	I50.9	1		
			Stroke / CVA	I63.9	3		
			Atherosclerosis	I70.9	2		
			Pneumonia	J12.82	69		
J00-J99	J	73	Bronchitis	J40	12		
			Chronic Obstructive Pulmonary Disease (COPD)	J44.9	3		
			Acute Respiratory Distress Syndrome	J80	1		
			Peptic Ulcer	K27	2		
K00-K93	K	7	Dyspepsia	K30	5		
			Hematemesis	K92.2	1		
L00-L99	L	1	Drug Eruption	L27	1		
			Chronic Kidney	N18	1		
N00-N99	N	4	CKD Stage 5	N18.5	1		
			Kidney Insufficiency	N19	1		
			Urinary tract infection	N39	1		
			Haemoptysis	R04.2	1		
R00-R99	R	36	Anosmia	R43.0	35		
			Ageusia	R43.2	32		
			U00-U99	U	100	Covid-19	U00

Table 4. Drug Use Profile

No	Drug Type	ATC Code	Percentage of Patients (%)	Drugs Used	Percentage of Drug Use (%)
1	Antiviral	J05AB16	83	Remdesivir	47
		J05AX27		Favipiravir	25
		J05A0H02		Oseltamivir	15
2	Antibacterial	J01FA10	91	Azithromycin	37
		J01MA14		Moxifloxacin	49
		J01MA12		Levofloxacin	40
		J01DC02		Cefuroxime	2
		J01DD02		Ceftazidime	11
		J01DD04		Ceftriaxone	29
		J01DD12		Cefoperozone	1
		J01DH02		Meropenem	36
		J01DA02		Amoxicillin	15
3	Analgesic	N02BB02	91	Metamizole	18
		R05DA04		Codeine	53
		N02BE01		Paracetamol	32
		N05BA01		analysis	8
		N02AA01		Morphine	3
		N01AH02		Fentanyl	2
4	Antihistamine	R06AE07	37	Setirizin	37
		R06AA11		Dimenhydrinate	2
5	Corticosteroids	A01AC03	70	Hydrocortisone	40
		A01AC02		Dexamethasone	32
		D07AA01		Methylprednisolone	27
6	Mucolytic	R05CB01	83	Acetylcysteine	83
7	5-HT3 Antagonist	A04AA01	20	Ondansetron	20
8	Diuretic	C03CA01	36	Furosemide	36
9	Antihypertensive	C09CA06	35	Candesartan	15
		C07AB07		Bisoprolol	22
		C08CA05		Nifedipine	1
		C08CA01		Amlodipine	14
		C08CA03		nicardipine	1
		C09CA03		Valsartan	1
		C01DA01		Lisinopril	1
10	Anticoagulants	B01AF01	45	Rivaroxaban	3
		B01AB01		Heparin	35
		B01AB05		Enoxaparin	14
		B01AX05		Fondaparinux	11
		B01AD05		Warfarin	12
11	Hypnosis and Anesthesia	N05BA12	47	Alprazolam	27
		N05BA01		Diazepam	15
		N05CD08		Midazolam	5
12	Antiplatelet	B01AC04	14	Clopidogrel	13
		B01AC06		aspirin	3
13	Antianginal	C01DA08	11	ISDN	11
		C08CA04		nicardipine	1
		C01EB15		myozidine	1
14	Hypolipidemic	C10AA05	33	Atorvastatin	9
		C01AA07		Rosuvastatin	23
		C10AB04		Gemfibrozil	3
		C10AB05		Fenofibrate	2
15	Antidiabetic	A10BF01	9	Levemir	9
16	Anti-ulcer	A10BF01	76	Acarbose	2
		A02BC03		Lansoprazole	8
		A02BC02		Pantoprazole	62
		A02BC01		Omeprazole	11
17	Supplement	A02BX02	85	Sucralfate	9
		A02BX01		Gabaxa/Amino acids	8

				Vipalbumin	10
				Sancoidan	2
				Curcuma	57
				Methylcobalamin	5
				Hepamax	11
				Synbiotic	20
				Prorenal	3
18	Vitamin	A11GA		Vitamin C	78
		A11CC		Vitamin D	26
			89	Furamin	12
				Zegavit	62
				Becom C/Z	23
19	Anti-Guat	M04AA01	4	Allopurinol	4
20	Vertigo		2	Betahistine Melisat	2
21	Psychosis and Similar Disorders	N05AD01	1	Haloperidol	1
22	Hemostatic and Antifibrinolytic	B02AA02	6	Tranexamic Acid	6
23	Anesthetic	L01XX11	6	Tramus	6
24	Urinary and Genital System	V03AE07	2	Aminoral	2
25	Shock and Hypotension	C01CA07	2	Dobutamine	2
26	Tricyclic Antidepressants	N06AA09	2	Amitriptyline	2
27	Nausea and vertigo	C10AB05		Fenofibrate	2
		A03FA01	2	Metoclopramide	5
		A03FA03		Domperidone	1
28	Laxative	A06AB02	8	Dulcolac	8
29	Cardiac Glycoside		2	Fargoxin	2
30	Antiasthma and Bronchodilators	A07EA06		Symbicort	1
			8	Ventolin	3
		R03DA05		Aminophylline	5
31	Immunoglobulins		3	IVIG	2
		J06BA		Intract	3

Table 5. Profile of DDD/100 Days of Hospitalization

ATC Code	Antibiotics	DDD in WHO	Number of grams	DDD/100 days in patient	Length of Days of Antibiotic Use (Days); Mean
J01FA10	Azithromycin	0,3	99,5	26,26	185; 5
J01MA14	Moxifloxacin	0,4	98,8	19,56	98; 2
J01DD04	Ceftriaxone	2	248	9,82	73; 2,5
J01DD12	Cefoperazone		8	0,16	8; 8
J01MA12	Levofloxacin	0,5	159,75	25,30	213; 15,3
J01DD02	Ceftazidime	4	138	2,73	69; 6,3
J01DH02	Meropenem	3	510	13,46	170; 4,7
J01DC02	Cefuroxime	3	6	0,16	6; 6
	Total		1268,05	97,44	822

Antibiotics are a class of drugs used in the treatment of COVID-19 patients. The antibiotics use activity was assessed from the accuracy of the antibiotic's selection. According to the 3rd Edition of Covid-19 Management Manual, it is explained that the recommended antibiotic therapy is Azithromycin or Levofloxacin when there is an indication of bacterial infection (PDPI et al., 2020). The assessment of accuracy in the antibiotic's selection refers to the initial diagnosis of Covid-19 patients.

Therefore, if there are no discrepancies such as the addition of other types of antibiotics, additional antibiotic therapy is maybe aimed at complications. According to the manual, the range of antibiotic use is 5-7 days (Gennaro et al., 2020).

The choice of antiviral therapy according to the Manual is Favipiravir and Remdesivir. Favipiravir is prescribed for the treatment of Covid-19. The use of this antiviral is limited to the treatment of cases that do not

improve with other antivirals. This drug is currently used as a test drug for Covid-19 (Lapostolle et al., 2020). The use of antivirals as therapy is used to suppress the virus development, not to destroy the entire virus. The correct choice of antiviral depends on the patient's diagnosis and the choice of the antiviral prescribed. Antiviral selection profiles were compared with those listed under the Covid-19 Management Manual 3rd Edition. The appropriate antiviral, according to the Manual, was Favipiravir or Remdesivir (PDPI et al., 2020).

CONCLUSION

Data shows that men are more exposed to Covid-19 than women. The condition of patients at the time of hospital admission was 44% moderate and 56% severe. Meanwhile, the condition of patients with moderate degree using antivirals and antibiotics at the time of hospital discharge was 84.1% recovered and 88.64% in improvement state. Meanwhile, the condition of patients with severe degrees using antivirals and antibiotics was 58.93% recovered and 58.92% in improvement state.

ACKNOWLEDGMENT

The author would like to express gratitude to all parties who have helped and supported this research, especially to the supervisors who have been willing to guide from the beginning to the end of the research.

AUTHOR CONTRIBUTIONS

Conceptualization, R.Y.; Software, V.Y.T.; Methodology, F.H.; Validation, F.H., R.K.; Formal Analysis, V.Y.T.; Investigation, F.H., R.K.; Resources, V.Y.T., A.K.J.; Data Curation, V.Y.T.; Writing - Original Draft, V.Y.T.; Writing - Review & Editing, F.H., R.K., A.K.J.; Visualization, V.Y.T.; Supervision, F.H., R.K., A.K.J.; Project Administration, V.Y.T., A.K.J.; Funding Acquisition, V.Y.T.

CONFLICT OF INTEREST

The authors report no conflict of interest in this study.

REFERENCES

Burhan E, Susanto AD, Nasution SA, Ginanjar E, Pitoyo W, Susilo A, et al. (2020). Guidelines for the Management of Covid - 19. ed.3, Jakarta December. <https://www.covid19treatmentguidelines.nih.gov/>. Accessed: 10 Oktober 2021.

Esmail, M. H., Jamaatic, N. D. R. Hakime, S., Maryam, M., Mirenayat, Mohsen S., Somayeh, L., N. K.,

K. (2022). Decreased serum levels of angiotensin converting enzyme (ACE)-2 and enhanced cytokine levels with severity of COVID-19: normalization upon disease recovery. *J Heliyon*: 8(2). <https://doi.org/10.1016/j.heliyon.2022.e08957>.

Gennaro, F. Di, Pizzol, D., Marotta, C., Antunes, M., Racalbutto, V., Veronese, N., Smith, L. (2020). *Coronavirus Diseases (COVID-19 Current Status and Future Perspectives: A Narrative Review*. International Journal of Environmental Research and Public Health, 17(2690), 1–11. doi: 10.3390/ijerph17082690.

Goncalves Mendes Neto A, Lo KB, Wattoo A, Salacup G, Pelayo J, DeJoy R, et al. (2020). Bacterial infections and patterns of antibiotic use in patients with COVID-19. *J Med Virol*. 1–7. doi: 10.1002/jmv.26441.

Gutierrez-Abejón E, Tamayo E, Martín-García D, Javier Álvarez F, Herrera-Gómez F. (2020). Clinical profile, treatment and predictors during the first Covid-19 wave: A population-based registry analysis from castile and leon hospitals. *Int J Environ Res Public Health*. 17(24):1–15. doi: 10.3390/ijerph17249360.

Hiroiyuki, N., Yosihiro, N., Hisako, M., Naoya, S., Akiko, S., Sathosi, K., The Japanese Respiratory Society, Scientific Assembly for Allergy, Immunology, and Inflammation. (2021). The prevalence of comorbid respiratory disease among COVID-19 patients, and mortality during the first wave in Japan: A nationwide survey by the Japanese Respiratory Society. *J Respiratory Investigation*. 59(5): 679-682. doi: <https://doi.org/10.1016/j.resinv.2021.06.008>.

Huipeng Ge, Xiufen Wang, Xiangning Yuan. (2020). The epidemiology and clinical information about COVID - 19, Springer-Verlag GmbH Germany. doi: 10.1007/s10096-020-03874-z.

Jordana, G. A., Coelho, R., Geovane M. F., Alice, A. L., Ágata L. R., Camila P. S., Martinsda, M. (2022). Ex-vivo mucolytic and anti-inflammatory activity of BromAc in tracheal aspirates from COVID-19. *J Biomedicine and Pharmacotherapy*: 148. https://www.researchgate.net/publication/358853000_Ex-vivo_Mucolytic_and_Anti_inflammatory_Activity_of_BromAc_in_Tracheal_Aspirates_From_COVID-19.

Kim MS, An MH, Kim WJ, Hwang T-H. (2020). Comparative efficacy and safety of pharmacological interventions for the treatment of COVID - 19: A systematic review and network meta analysis. *PLoS Med* 17(12). doi: 10.1371/journal.pmed.1003501.

Lapostolle, F., Schneider, E., Vianu, I., Dollet, G., Roche, B., Berdah, J., Adnet, F. (2020). Clinical Features of 1487 COVID-19 Patients with Outpatient Management in the Greater Paris : the

- COVID - Call Study. Internal and Emergency Medicine. doi: 10.1007/s11739-020-02379-z.
- Laura, S., Catherine, K. E., Salma, M. A., Elizabeth, C., Kimberly, D., Kevin, J. L., Sandro, G. (2021). Financial hardship and health risk behavior during COVID-19 in a large US national sample of women. *J Population Health*. 13. doi: 10.1016/j.ssmph.2021.100734.
- Luis, F.R., Alejandro, R., Alirio, B. D. P., Tanouxa, Y. V. Fuentes, Esteban G. G., M. LIVEN-COVID-19 Investigators and COVID-19 SEMICYUC Study Group. (2022). Dexamethasone as risk-factor for ICU-acquired respiratory tract infections in severe COVID-19. *J Critical Care*, 69. doi: 10.1016/j.jccr.2022.154014.
- Naoyuki, M., Yashuhi, N., Makoto, O., naoki, F., Akihisa, Y., Yoshihisa, I., Shosaku, N. (2022). Early identification of novel coronavirus (COVID-19) pneumonia using clinical and radiographic findings. *J Infection and Chemotherapy*. 28(5): 718-721. doi: 10.1016/j.jiac.2022.02.005.
- PDPI, PERKI, PERDATIN, IDAI, Covid-19 Administration Guidelines 3rd edition, Jakarta, December 2020.
<https://www.papdi.or.id/pdfs/983/Buku%20Pedoman%20Tatalaksana%20COVID19%205OP%20Edisi%203%202020.pdf>. Accessed: 20 January 2022.
- Rodrigo da Rosa Mesquita, Luiz Carlos Francelino Silva Junior, Fernanda Mayara Santos Santana. (2020). Clinical manifestations of COVID-19 in the general population: systematic review, Springer-Verlag GmbH Austria, part of Springer Nature. doi: <https://doi.org/10.3390/jcm10102201>.
- Setiadi AP, Wibowo YI, Halim S V., Brata C, Presley B, Setiawan E. (2020). Therapeutic Management of Patients with COVID - 19: A Narrative Study. *Indones J Clin Pharm*. 9(1):70. doi: 10.15416/ijcp.2020.9.1.70.
- Singh TU, Parida S, Lingaraju MC, Kesavan M, Kumar D, Singh RK. (2020). Drug *repurposing approach to fight COVID - 19*. *Pharmacol Reports*. 72(6):1479–508. doi: 10.1007/s43440-020-00155-6.
- Somers EC, Eschenauer GA, Troost JP, Golob JL, Gandhi TN, Wang L. (2020). Tocilizumab for treatment of mechanically ventilated patients with COVID - 19. *medRxiv*. doi: 10.1093/cid/ciaa954.
- Tsamrotul Ilmi, Rika Yulia, Fauna Herawati. (2020). Evaluation of the use of antibiotics in pneumonia patients at the Tulungagung Regional General Hospital, Surabaya.
https://www.researchgate.net/publication/344643349_EVALUASI_PENGGUNAAN_ANTIBIOTIK_PADA_PASIEN_PNEUMONIA_DI_RUMAH_SAKIT_UMUM_DAERAH_TULUNGAGUNG. Accessed: 10 February 2022.
- Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. (2020). Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID - 19): A Review. *JAMA - J Am Med Assoc*: 324(8):782–93. doi: 10.1001/jama.2020.12839.
- World Health Organization. (2021). *Covid-19 Clinical Management Living Guidedance*. <https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-2>. Accessed: 20 January 2022.

Vol. 9 No. 2 August 2022



Jurnal Farmasi dan Ilmu Kefarmasian Indonesia

E-ISSN: 2580-8303
P-ISSN: 2406-9388



PUBLISHED BY:
FACULTY OF PHARMACY UNIVERSITAS AIRLANGGA in collaboration with
INDONESIAN PHARMACISTS ASSOCIATION (IAI) OF EAST JAVA



Accredited SINTA 2
No: B/1796/E5.2/KI.02.00/2020

Editorial Team



Elida Zairina, S.Si., MPH., PhD., Apt
Editor in Chief

Universitas Airlangga, Indonesia



0000-0003-0845-4640

OMQtYSgAAAAJ

56127288100



5986180



Suciati, S.Si., M.Phil, PhD., Apt
Editorial Board

Universitas Airlangga, Indonesia



0000-0003-2436-4119

5u1wAAAAJ

36453244400



5987657



Dr. rer. nat Maria Lucia Ardhani Dwi Lestari, S.Si., M.Pharm, Apt
Editorial Board

Universitas Airlangga, Indonesia



0000-0001-6111-1562

bUdnDcKAAAAJ

35573993500



5986185



Prof. Dewi Melani Hariyadi, S.Si, M.Phil., PhD., Apt.
Editorial Board

Universitas Airlangga, Indonesia



0000-0001-9357-3913

iNROAAAAJ

36620858200



5977392



Dr. Wiwied Ekasari, M.Si., Apt.
Editorial Board

Universitas Airlangga, Indonesia



0000-0003-3163-5829

g_MODU8AAAAJ

21733773200



5986166



Dr. Yunita Nita, S.Si., M.Pharm., Apt.
Editorial Board

Universitas Airlangga, Indonesia



0000-0001-8918-2901

JmDIF50AAAAJ

8358439700



5992800



Chrismawan Ardianto, S.Farm., M.Sc., Ph.D., Apt.

Editorial Board

Universitas Airlangga, Indonesia



0000-0003-3713-7900

DFvWUZYAAAAJ

56919638800 5989459



Tutik Sri Wahyuni, S.Si., M.Si., Ph.D., Apt.

Editorial Board

Universitas Airlangga, Indonesia



0000-0002-0577-5468

FA26mmAAAAAJ

29167652500 5986177



Helmy Yusuf, S.Si., MSc., Ph.D., Apt.

Editorial Board

Universitas Airlangga, Indonesia



0000-0001-5929-4726

PJi1npsAAAAJ

56232661400 5986187



Didik Setiawan, Ph.D., Apt

Editorial Board

Universitas Muhammadiyah Purwokerto, Indonesia



0000-0001-9104-548X

jPV689gAAAAJ

56543713300 5972747



Dr. Susi Ari Kristina, M.Kes., Apt

Editorial Board

Universitas Gadjah Mada, Indonesia



0000-0003-4248-6830

IsSNzIAAAAAJ

56626120200 6001684



Dr. Ariyanti Suhita Dewi, S.Si., M.Sc

Editorial Board

Kementerian Kelautan dan Perikanan, Indonesia



0000-0002-9293-4091

gFILRr4AAAAJ

36159404300 6670048



Dr. Adliah Mhd. Ali

Editorial Board

Universiti Kebangsaan Malaysia, Malaysia



0000-0003-1306-8330

b4rrTOUAAAAJ

55141172000





Asst. Prof. Dr. Nungruthai Suphrom

Editorial Board

Naresuan University, Thailand

0000-0003-3767-8387 ZqxeBAQxUcIC 54388285100 -



Assist. Prof. Dr.rer.nat. Nuttakorn Baisaeng

Editorial Board

University of Phayao, Thailand

0000-0002-0305-5854 ylMPyhkAAAAJ 55630412100 -



Debra Dorotea, Ph.D.

Editorial Board

Karolinska Institute, Sweden

0000-0002-5302-0617 7A3VivgAAAAJ 57196217112 -



Deby Fapyane, Ph.D.

Editorial Board

Cellugy ApS, Denmark

0000-0003-1408-3030 t4FEn98AAAAJ 55711006200 -



Prof. Dr. Alfi Khatib

Editorial Board

Kulliyah of Pharmacy, International Islamic University Malaysia, Malaysia

0000-0002-5480-0789 MAAAAJ 12140192900 -



Dr. Long Chiau Ming

Editorial Board

Universiti Brunei Darussalam, Brunei

0000-0002-6971-1383 5Gn6o5QAAAAJ 55745857500 -



Tina Tran, PharmD

Editorial Board

Temple University, USA

0000-0002-8332-8196 - 57192086006 -



Susmiandri, S.Kom

Administrative Editor

Universitas Airlangga, Indonesia

- - -

Vol. 9 No. 2 (2022): JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA

Current Issue



Vol. 9 No. 2 (2022): JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA

The articles in this issue were authored/co-authored by authors from Indonesia, Malaysia, and Japan.


Published: 2022-08-31

Full Issue

 PDF

Articles

A Community's Knowledge and Attitude in Recognizing Symptoms and Diarrhea Management in Children

 Arina Dery Puspitasari , Novitri Wulandari , Bindaria Mutmaina Prabawati , Liza Yudistira Yusan



101-106

 Abstract : 1281



PDF : 741

 PDF

 DOI : 10.20473/jfiki.v9i22022.101-106

Effect of Sodium Alginate Concentration on Characteristics, Stability and Drug Release of Inhalation Quercetin Microspheres

 Tekla Kalalo , Andang Miatmoko , Hanafi Tanojo , Tristiana Erawati , Dewi Melani Hariyadi , Noorma Rosita



107-114

 Abstract : 1403




PDF : 788


 PDF


 DOI : 10.20473/jfiki.v9i22022.107-114

Characteristic and Physical Stability of Anti-Aging Green Tea Extract (GTE) on NLC with Argan Oil as Liquid Lipid



 Anita Natalia Suryawijaya , Tutiek Purwanti , Djoko Agus Purwanto , Widji Soeratri

 115-124


 Abstract : 1100


 PDF : 682

 PDF

 DOI : 10.20473/jfiki.v9i22022.115-124

Anti-Hepatitis C Activity of Combination of Ruta angustifolia Extract and Ribavirin

 Tutik Sri Wahyuni , Adita Ayu Permatasari , Chie Aoki-Utsubo , Aty Widyawaruyanti , Achmad Fuad

 125-130


 Abstract : 870


 PDF : 301

 PDF

 DOI : 10.20473/jfiki.v9i22022.125-130

Delivering a Birth Safely – Case Reports of Perineal Infection Prevention among Pregnant Women Living Around Ex-landfills

 Lisa Herliyana , Anita Purnamayanti , Fransiscus Octavianus Hari Prasetyadi

 131-137


 Abstract : 689


 PDF : 267

 PDF

 DOI : 10.20473/jfiki.v9i22022.131-137

Assessment of Antibiotic Use in ICU Patients with Pneumonia Using ATC/DDD as a Quantitative Analysis Method

 Mareta Rindang Andarsari , Zedny Norachuriya , Sarah Mahmudatun Nabila , Toetik Aryani , Alfian Nur Rosyid

 138-145


 Abstract : 1047

 PDF : 785

 PDF

 DOI : 10.20473/jfiki.v9i22022.138-145

Formulation and Characterization of Carbamazepine Chitosan Nanoparticle

 Citra Ariani Edityaningrum , Ariza Nur Zulaechah , Widyasari Putranti , Dewa Ayu Arimurni

 146-154


 Abstract : 621


 PDF : 486

 PDF

 DOI : 10.20473/jfiki.v9i22022.146-154

Analysis of Factors Affecting the Stress Level and Self-Medication Practice in Primary Dysmenorrhea in Adolescents during COVID-19 Pandemic

 Nurul Kusumawardani , Endang Darmawan , Jasmine Amira Hatisuci , Iftita Nuratika , Ramadhanti , Rahma Sakti Oktavia , Very Ainun Fauziah , Trisna Styawaty , Ratih Nugraeni

 155-167


 Abstract : 757

 PDF : 419

 PDF

 DOI : 10.20473/jfiki.v9i22022.155

Analysis of Drug Use in Non-Ventilator Covid-19 Patients at Bangil Hospital

 Vincentina Yenny Triamyanti , Fauna Herawati , Rika Yulia , Abdul Kadir Jaelani

 168-176


 Abstract : 458

 PDF : 164

 PDF

 DOI : 10.20473/jfiki.v9i22022.168-176

Direct Medical Cost Analysis of Dengue Patients: A Retrospective Study

 Imaniar Noor Faridah , Tuty Lia Syahfitri , Reza Aditya Nugroho , Woro Supadmi , Haafizah Dania , Dyah Aryani Perwitasari



177-184


 Abstract : 546

 PDF : 463

 PDF

 DOI : 10.20473/jfiki.v9i22022.177-184

Acute and Subchronic Toxicity of Indonesian House Dust Mites (IHDM) Allergenic Extract for Asthma Allergy Immunotherapy

 Aniek Setiya Budiatin , Yusuf Alif Pratama , Winda Fatma Sari , Mahardian Rahmadi , Muhammad Taher , Zainul Amiruddin Zakaria , Junaidi Khotib



185-192


 Abstract : 715

 PDF : 282

 PDF

 DOI : 10.20473/jfiki.v9i22022.185-192

The ABC Analysis of Drug Use and Cost in Cardiology Outpatients -National Health Insurance

 Budi Suprapti , M. Yusuf , Marcha Debby Saraswati , Selvia Febriana Astuti , Dewi Damayanti



193-199

 Abstract : 492

 PDF : 167

 PDF

 DOI : 10.20473/jfiki.v9i22022.193-199

Analysis of Antibiotic Use in COVID-19 Patients at a Hospital in Sidoarjo

 Weni Kristanti , Rika Yulia , Fauna Herawati

 200-208

 Abstract : 515

 PDF : 543

 PDF

 DOI : 10.20473/jfiki.v9i22022.200-208

Login

Username *

Password *



Forgot your password?

Keep me logged in

Login

Register

Accredited Sinta II



Instructions

Guide for Reviewers

Guide for Authors

Online Submission

Document Template

Copyright Form

Journal Policy

Focus and Scope

Publication Ethics

Article Processing Charge

Peer Review Process

Peer Review

Editorial Team

Open Access Statement

Archiving

Plagiarism

Copyright

Contact

Old Website

Publisher

This journal has been published by the **Faculty of Pharmacy, Universitas Airlangga** in collaboration with **IAI of East Java** and **Center of Excellence for Patient Safety and Quality**



Meet Our Editorial Team



Elida Zairina, S.Si., MPH., Ph.D., Apt.
Editor in Chief
Universitas Airlangga, Indonesia

-



Suciati, S.Si., MPhil., Ph.D., Apt.
Editorial Board
Universitas Airlangga, Indonesia

-



Susmiandri, S.Kom.
Assistant Editor
Universitas Airlangga, Indonesia

-

[Read More](#)

ISSN



9 772406 938003

P-ISSN



Indexing



More Indexing...



Citation Analysis



Visitors



Keywords



Address

Fakultas Farmasi Universitas Airlangga
Jl. Dr. Ir. H. Soekarno, Mulyorejo, Surabaya,

(Faculty of Pharmacy Universitas Airlangga)
Jawa Timur - 60115, Indonesia

Contact Info:

Telp: 6231-5937824

Fax: 6231-5932549

Email: jfiki@ff.unair.ac.id



Lembaga Inovasi, Pengembangan Jurnal,
Penerbitan dan Hak Kekayaan Intelektual

LIPJPHKI

Gedung AUP, Kampus C, Universitas Airlangga, Kota Surabaya, Jawa Timur, 60115

This work is licensed under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](https://creativecommons.org/licenses/by-nc-sa/4.0/).





JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA

[FAKULTAS FARMASI UNIVERSITAS AIRLANGGA](#)

✳ P-ISSN : 24069388 < > E-ISSN : 25808303



3.25

Impact Factor



969

Google Citations



Sinta 2

Current Accreditation

[Google Scholar](#)

[Garuda](#)

[Website](#)

[Editor URL](#)

History Accreditation

2017

2018

2019

2020

2021

2022

2023

2024

[Garuda](#)

[Google Scholar](#)

[Molecular Docking: Bioactive Compounds in Indramayu Mango \(*Mangifera indica* L.\) Peel Waste as NS5B Hepatitis C Virus \(HCV\) Inhibitor](#)

Universitas Airlangga [JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA Vol. 10 No. 1 \(2023\): JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA 1-10](#)

📅 2023 [DOI: 10.20473/jfiki.v10i12023.1-10](#) [Accred : Sinta 2](#)

[Anti-Inflammatory Effect of Red Dragon Fruit \(*Hylocereus polyrhizus*\) Peel on Male White Rat](#)

Universitas Airlangga [JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA Vol. 10 No. 1 \(2023\): JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA 22-29](#)

📅 2023 [DOI: 10.20473/jfiki.v10i12023.22-29](#) [Accred : Sinta 2](#)

[Molecular Docking of Bicycloproline Derivative Synthetic Compounds on Envelope Protein: Anti-SARS-CoV-2 Drug Discovery](#)

Universitas Airlangga [JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA Vol. 10 No. 1 \(2023\): JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA 11-21](#)

📅 2023 [DOI: 10.20473/jfiki.v10i12023.11-21](#) [Accred : Sinta 2](#)

[Characterization of Spanlastic System Loaded Green Tea Extract as Antioxidant for Skin](#)

Universitas Airlangga [JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA Vol. 10 No. 1 \(2023\): JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA 30-37](#)

2023 DOI: 10.20473/jfiki.v10i12023.30-37  Accred : Sinta 2

[Study of Growth Curve of Lactobacillus plantarum FNCC 0026 and Its Antibacterial Activity](#)

Universitas Airlangga  [JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA Vol. 10 No. 1 \(2023\); JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA 38-43](#)

2023 DOI: 10.20473/jfiki.v10i12023.38-43  Accred : Sinta 2

[Effect of Different Lipid Ratios on Physicochemical Stability and Drug Release of Nanostructured Lipid Carriers Loaded Coenzyme Q10](#)

Universitas Airlangga  [JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA Vol. 10 No. 1 \(2023\); JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA 44-53](#)

2023 DOI: 10.20473/jfiki.v10i12023.44-53  Accred : Sinta 2

[The Effect of Polymers Ratio Carboxymethyl Chitosan, Polyvinyl Pyrolidone K-30, and Ethyl Cellulose N22 on Physico-Chemical Characteristics and Drug Release from Matrix Type Diclofenac Potassium Patch](#)

Universitas Airlangga  [JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA Vol. 10 No. 1 \(2023\); JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA 54-61](#)

2023 DOI: 10.20473/jfiki.v10i12023.54-61  Accred : Sinta 2

[Characteristics and Physical Stability of Nanoemulsion as a Vehicle for Anti-Aging Cosmetics: A Systematic Review](#)

Universitas Airlangga  [JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA Vol. 10 No. 1 \(2023\); JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA 62-85](#)

2023 DOI: 10.20473/jfiki.v10i12023.62-85  Accred : Sinta 2

[Growth Inhibitory Effects of Red and Yellow Passion Fruits against MRSA and ESBL-producing Bacteria](#)

Universitas Airlangga  [JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA Vol. 10 No. 1 \(2023\); JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA 86-91](#)

2023 DOI: 10.20473/jfiki.v10i12023.86-91  Accred : Sinta 2

[Cost of Illness Study in Thyroid Patients: A Systematic Review](#)

Universitas Airlangga  [JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA Vol. 10 No. 1 \(2023\); JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA 92-102](#)

2023 DOI: 10.20473/jfiki.v10i12023.92-102  Accred : Sinta 2

[View more ...](#)